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Oﬁcial de la Federación, 23-04-07). Results are expressed as AE
or its treatment cost in US dollars. RESULTS: Eight oncologists
participated in the Panel. Consensus was achieved for all items
after the questionnaire’s second ﬁlling round. Second line treat-
ment for NSCLC cost estimate was $5377.46 (includes four
chemotherapy cycles with docetaxel, administration costs and
premedication costs). Estimated cost for AEs per event was: RA
$112.13, AN $140.50, NS $194.56, VO $243.08, DR $243.64,
HS $251.56, NP $495.27, TC $948.00, PNA $1167.02, DS
$1807.86, AX $1939.88, ST $2055.82, FN $2527.39, and ILD
$5189.02. CONCLUSION: ILD was the most expensive AE due
to NSCLC treatment, while the most costly were those incurring
in emergency room visits and/or patient hospitalization.
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OBJECTIVE: Non-melanoma skin cancer incidence is increasing
yet no speciﬁc guidelines for treatment selection exist. Reports
vary on surgical treatment efﬁcacy, and treatment choice may be
based in-part on costs, despite little comparative cost informa-
tion. We compared 2007 treatment costs of the three most
common nonmelanoma skin cancer treatments: tumor destruc-
tion by ED&C, excision, and histologically-guided serial excision
(Mohs surgery). METHODS: We studied 936 consecutive non-
melanoma skin cancers diagnosed in 1999–2000 in a university-
afﬁliated dermatology practice. Clinical and utilization data were
obtained from patient surveys and medical records. We deter-
mined cost of treatments, repairs, pathology, and biopsies based
on size, lesion location, number of Mohs stages, medications,
and physician visits, using CPT codes and Medicare fees. We
controlled for procedure risk-selection factors in our sample.
RESULTS: A total of 27.2% of lesions were treated with ED&C,
29.2% with excision, and 43.6% with Mohs surgery. The
weighted average costs per lesion for initial treatment for ED&C,
excision, and Mohs were $221, $529, and $1287, respectively.
When wound repairs, pathology, drug costs and follow-up
physician visits were included, costs rose to $646, $1531, and
$2805. When controlling for risk selection using Mohs sample
for baseline risk, initial costs changed little ($232, $578, $1287).
However, when adding all costs to the controlled sample, the
totals rose to $1750, $2096, and $2805, and differences across
treatments diminished. The uncontrolled costs of Mohs proce-
dure itself (46%) accounts for a greater percentage of total costs
compared with the other two procedures (35%, 34%), and more
than subsequent repair costs (31%, 20% 2%). CONCLUSION:
Mohs surgery was the most costly procedure, however cost dif-
ferences across treatments diminished when controlling for treat-
ment selection factors. This is the ﬁrst cost study which compares
surgical treatment costs using the new (2007) Medicare/CPT
costing rules allowing higher payments for increased complexity
of lesion location.
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OBJECTIVE: To assess the impact of the human immunodeﬁ-
ciency virus (HIV) on the pathogenesis of human papillomavirus
(HPV) infection, precancerous lesions, invasive cervical cancer,
and total treatment costs in South African women. Invasive
cervical cancer is the second most common cancer among South
African women. The high prevalence of HIV in South Africa
(18%) is likely a contributing factor to the high rates of cervical
cancer, as immunocompromised patients are at higher risk of
HPV infection and associated precancerous lesions. METHODS:
We developed a lifetime Markov simulation model of the natural
history of cervical neoplasia and HIV infection. The model was
used to predict the impact of HIV and acquired immunodeﬁ-
ciency syndrome (AIDS)-related mortality on the course of cer-
vical disease in a hypothetical cohort of 100,000 South African
women. Clinical data were based on published South African
literature, high-quality clinical studies, and expert opinion. Risk
of progression of HIV/AIDS was based on CD4 cell counts and
viral load levels. Primary outcome measures included lifetime
risk of cervical intraepithelial neoplasia and cervical cancer, years
of life saved, quality-adjusted life years saved (QALYs), and total
lifetime costs. RESULTS: Lifetime risk of cervical cancer ranged
from 2.3% among HIV-negative women to 3.3% in HIV-positive
women. In a cohort of 100,000 women, the high rate of HIV
infection in South Africa led to an additional 5200 HPV infec-
tions, 490 cervical cancers, and 175 cervical cancer deaths. HIV
infection decreased average life expectancy among South African
women by 3.31 years or 3.28 QALYs and increased costs by
approximately Rand 21,400 per woman. CONCLUSION: HIV
infection contributes to higher rates of invasive cervical cancer
and increases costs. Given the high prevalence of HIV infection in
South Africa, more frequent cervical cancer screening for HIV-
positive women may be warranted.
PCN48
LONGITUDINAL COMPARISON ACROSSTREATMENTS, RISK
AND AGE OFWORK LOSS COSTS IN PROSTATE CANCER
PATIENTS: 10YEAR PATTERNS
Wilson L1, Liang SY1, Kwon P2,Tesoro RV3, Sadetsky N1,
Greene KL1, Broering JM1, Carroll PR1
1University of California, San Francisco, San Francisco, CA, USA,
2University of California, San Francisco, San Francsico, CA, USA,
3Loma Linda University Medical Center, Loma Linda, CA, USA
OBJECTIVE: The few workloss studies of prostate cancer
patients are short-term and single-treatment focused. We
compare long-term patterns of workloss and costs of 5414 newly
diagnosed patients over 10 years stratiﬁed by treatment type, age
and risk group. METHODS: Workloss patterns for prostate
cancer were identiﬁed using CaPSURE, a national disease registry
that includes clinical data and patient-reported outcome ques-
tionnaires, including demographics, co-morbidity, risk, and work
patterns at 31 academic and community urology practices. Both
change in work status (decreased if changed from full to part-
time or disability, increased if changed back to full time, or no
change) and hours lost were assessed at six-month intervals over
ten years. National hourly wages were used to determine work-
loss costs by age, disease risk, and treatment type. RESULTS:
Patients reported average weekly work reductions of 15.7 hours
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